# HemLibra Prophylaxis in Patients With Hemophilic Pseudotumor

> **NCT03921294** · PHASE4 · TERMINATED · sponsor: **Indiana Hemophilia &Thrombosis Center, Inc.** · enrollment: 1 (actual)

## Conditions studied

- Haemophilic Pseudotumour

## Interventions

- **DRUG:** Emicizumab

## Key facts

- **NCT ID:** NCT03921294
- **Lead sponsor:** Indiana Hemophilia &Thrombosis Center, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-15
- **Primary completion:** 2022-03-16
- **Final completion:** 2022-03-16
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Global COVID-19 pandemic prevented further study visits or enrollment.
- **Last updated:** 2024-04-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03921294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03921294, "HemLibra Prophylaxis in Patients With Hemophilic Pseudotumor". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03921294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*